Literature DB >> 12895137

Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

Frank Lopez1, Raul Silva, Linda Pestreich, Rafael Muniz.   

Abstract

OBJECTIVES: The primary objective was to compare the differences in clinical efficacy of the starting dose of Ritalin LA (20mg) to the starting dose of Concerta (18mg), in a laboratory school setting for the duration of an entire school day. Secondary objectives were to compare Ritalin LA 20mg with Concerta 36mg, and Ritalin LA and both Concerta doses versus placebo across the school day.
METHODS: Thirty-six children (29 males, 7 females), aged 6-12 years, with attention deficit hyperactivity disorder, previously stabilized on methylphenidate (MPH), completed this four-way, randomized, single-blind crossover, analog classroom study. Patients were evaluated on day 0 and randomized to receive treatment on days 7, 14, 21, and 28 (Ritalin LA 20mg, Concerta 18mg, Concerta 36mg, or placebo).
RESULTS: Swanson, Kotkin, Agler, M-Flynn and Pelham Rating Scale (SKAMP)-attention: The effect of Ritalin LA 20mg across the morning was statistically different from that of Concerta 18mg and 36mg, as demonstrated by the change in the area under the curve (AUC) during the first 4 hours (0-4) from pre-dose. AUC((0-4)) for RitalinLA was -2.48 versus -1.36 for Concerta 18mg (p = 0.015), and -1.55 for Concerta 36mg (p = 0.043). AUC((0-8)) change from pre-dose for Ritalin LA was -4.48 versus -2.72 for Concerta 18mg (p = 0.074), and -3.24 for Concerta 36mg (p = 0.208).SKAMP-deportment: AUC((0-4)) for Ritalin LA was -1.67 compared with -0.28 for Concerta 18mg (p < 0.001), and -0.55 for Concerta 36mg (p = 0.004). AUC((0-8)) change from pre-dose for Ritalin LA was -2.81 compared with -0.82 for Concerta 18mg (p = 0.018), and -1.34 for Concerta 36mg (p = 0.078).Combined: Mean AUC((0-4)) change from pre-dose for Ritalin LA was -2.05 compared with -0.78 for Concerta 18mg (p < 0.001), -1.01 for Concerta 36mg (p = 0.003). The mean AUC((0-8)) change from pre-dose for Ritalin LA was -3.58 compared with -1.70 for Concerta 18mg (p = 0.010), -2.22 for Concerta 36mg (p = 0.061). Math test-attempted: Mean pre-dose score for Ritalin LA was about 73 compared with 74, 90, and 81 for Concerta 18mg, 36mg, and placebo, respectively. Mean AUC((0-8)) change from pre-dose for Ritalin LA was 202 compared with 115 for Concerta 18mg (p = 0.135), 137 for Concerta 36mg (p = 0.265). Math test-correct: Mean pre-dose score for Ritalin LA was 68 compared with 64, 78, and 76 for Concerta 18mg, 36mg, and placebo, respectively. Mean AUC((0-8)) change from pre-dose for Ritalin LA was 183 compared with 100 for Concerta 18mg (p = 0.144), and 117 for Concerta 36mg (p = 0.245). SAFETY: One patient from each treatment group experienced a single mild adverse event that included abdominal pain, nausea, and dyspnea.
CONCLUSION: While both Ritalin LA and Concerta were shown to be effective, the different release profiles of each formulation can result in distinct differences between the effects on measures of attention and deportment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895137     DOI: 10.2165/00148581-200305080-00005

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  9 in total

1.  Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.

Authors:  J Swanson; S Gupta; D Guinta; D Flynn; D Agler; M Lerner; L Williams; I Shoulson; S Wigal
Journal:  Clin Pharmacol Ther       Date:  1999-09       Impact factor: 6.875

Review 2.  Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.

Authors:  B Vitiello
Journal:  CMAJ       Date:  2001-11-27       Impact factor: 8.262

3.  Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground.

Authors:  James M Swanson; Suneel Gupta; Lillie Williams; Dave Agler; Marc Lerner; Sharon Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-11       Impact factor: 8.829

4.  Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.

Authors:  J Swanson; S Wigal; L Greenhill; R Browne; B Waslick; M Lerner; L Williams; D Flynn; D Agler; K L Crowley; E Fineberg; R Regino; M Baren; D Cantwell
Journal:  Psychopharmacol Bull       Date:  1998

5.  Reliability and validity of the SKAMP rating scale in a laboratory school setting.

Authors:  S B Wigal; S Gupta; D Guinta; J M Swanson
Journal:  Psychopharmacol Bull       Date:  1998

6.  Parent-teacher concordance for DSM-IV attention-deficit/hyperactivity disorder in a clinic-referred sample.

Authors:  E M Mitsis; K E McKay; K P Schulz; J H Newcorn; J M Halperin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-03       Impact factor: 8.829

7.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

8.  Increased methylphenidate usage for attention deficit disorder in the 1990s.

Authors:  D J Safer; J M Zito; E M Fine
Journal:  Pediatrics       Date:  1996-12       Impact factor: 7.124

9.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  9 in total
  22 in total

1.  Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Authors:  Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Richard Hansen
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

2.  Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis.

Authors:  Holly Kimko; Ekaterina Gibiansky; Leonid Gibiansky; H Lynn Starr; Joris Berwaerts; Joseph Massarella; Frank Wiegand
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-22       Impact factor: 2.745

Review 3.  Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.

Authors:  Tobias Banaschewski; David Coghill; Paramala Santosh; Alessandro Zuddas; Philip Asherson; Jan Buitelaar; Marina Danckaerts; Manfred Döpfner; Stephen V Faraone; Aribert Rothenberger; Joseph Sergeant; Hans-Christoph Steinhausen; Edmund J S Sonuga-Barke; Eric Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-05-05       Impact factor: 4.785

Review 4.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 5.  Review and comparison of the long acting methylphenidate preparations.

Authors:  Feng Liu; Rafael Muniz; Haruka Minami; Raul R Silva
Journal:  Psychiatr Q       Date:  2005

6.  Attention deficit/hyperactivity disorder: pharmacotherapy.

Authors:  Josephine Elia
Journal:  Psychiatry (Edgmont)       Date:  2005-01

7.  Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial.

Authors:  Manfred Döpfner; Claudia Ose; Roland Fischer; Richard Ammer; André Scherag
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-07-26       Impact factor: 2.576

Review 8.  A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Franziska Minder; Agnieszka Zuberer; Daniel Brandeis; Renate Drechsler
Journal:  Child Psychiatry Hum Dev       Date:  2018-08

9.  Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.

Authors:  Manfred Döpfner; Wolff Dieter Gerber; Tobias Banaschewski; Dieter Breuer; Franz Joseph Freisleder; Gabi Gerber-von Müller; Michael Günter; Frank Hässler; Claudia Ose; Aribert Rothenberger; Klaus Schmeck; Judith Sinzig; Christina Stadler; Henrik Uebel; Gerd Lehmkuhl
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

10.  The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.

Authors:  Lawrence Maayan; Natalya Paykina; Jane Fried; Tara Strauss; S Sonia Gugga; Laurence Greenhill
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-04       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.